Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities.

Biomolecules·2026
Same author

Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers.

International journal of molecular sciences·2024
Same author

Correction: Soung et al. Therapeutic Potential of Chemically Modified MiR-489 in Triple-Negative Breast Cancers. <i>Cancers</i> 2020, <i>12</i>, 2209.

Cancers·2024
Same author

The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489.

Cells·2024
Same author

Effect of Preoperative Opiate Use on Outcomes After Posterior Lumbar Surgery.

Cureus·2022
Same author

Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers.

Cancers·2020

Related Experiment Video

Updated: Jul 12, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.0K

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance.

Young-Hwa Soung1, Jun Chung1

  • 1Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.

Biomolecules
|October 28, 2023
PubMed
Summary
This summary is machine-generated.

Poly(ADP-ribose) polymerase (PARP) inhibitors offer a promising cancer therapy for HRR-deficient tumors. This review explores PARP inhibitor mechanisms, resistance, and novel combination strategies to improve patient outcomes.

Keywords:
PARP inhibitorsPARP-1breast cancerscombination therapyhomologous recombination deficiencyovarian cancersresistance

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Related Experiment Videos

Last Updated: Jul 12, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.0K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly(ADP-ribose) polymerase (PARP) enzymes are crucial for DNA repair, particularly homologous recombination repair (HRR).
  • Cancers with defects in HRR pathways, such as those with BRCA1/2 mutations, are susceptible to PARP inhibitors (PARPis) via synthetic lethality.
  • PARPis represent a significant therapeutic advance for advanced ovarian and breast cancers with HRR deficiencies.

Purpose of the Study:

  • To review the molecular mechanisms underlying the therapeutic action of PARP inhibitors.
  • To summarize the known mechanisms of acquired resistance to PARP inhibitors.
  • To discuss emerging combination treatment strategies to overcome PARP inhibitor resistance.

Main Methods:

  • Literature review of studies on PARP enzyme function, DNA repair, and cancer therapeutics.
  • Analysis of molecular mechanisms of PARP inhibitor action and resistance.
  • Synthesis of current research on combination therapies involving PARPis.

Main Results:

  • PARP inhibition effectively targets cancers with HRR defects, leading to synthetic lethality.
  • Acquired resistance to PARPis is a common challenge, limiting their efficacy in some patients.
  • Emerging combination strategies show potential for enhancing PARPis' effectiveness and overcoming resistance.

Conclusions:

  • PARP inhibitors are valuable in treating HRR-deficient cancers, but resistance necessitates further research.
  • Understanding resistance mechanisms is key to developing more effective treatment regimens.
  • Combination therapies hold promise for improving clinical outcomes in patients treated with PARPis.